Talha Azam Tarrar, Muhammad Yasir Anwar, Muhammad Ashar Ali, Memoona Saeed, Sana Rehman, Shammas F Bajwa, Tooba Ayub, Haleema Javid, Rimsha Ali, Alaa Irshad, and Wajeeha Aiman
Background Multiple patients with prostate cancer become resistant to castration therapies, which is termed castration-resistant prostate cancer (CRPC). Purpose The purpose of this review is to assess the status of efficacy (≥50% decline in prostate-specific antigen (PSA), progression-free survival (PFS), and overall survival (OS)) and safety (grade 3-4 adverse effects) of monoclonal antibodies in CRPC. Data source We searched databases including PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov. Results Hazard ratios of PFS and OS were 0.77 (95% CI = 0.69-0.87, I